Indirect Sales To Wholesalers was Elite Pharmaceuticals’s largest product and service line in fiscal 2026, bringing in $82.54M of $149.93M (55%).
| Product and Service | FY 2011 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Indirect Sales To Wholesalers | — | — | $33.98M | $82.54M | |||||||
| Direct Sales To Wholesalers | — | — | $48.01M | $65.27M | |||||||
| Manufacturing | $29.19M | $54.12M | — | — | |||||||
| Generic Products Anda | — | — | — | — | |||||||
| Manufactured Product, Other | — | — | — | — | |||||||
| Lodrane Products | — | — | — | — | |||||||
| Licensing | $4.97M | $2.50M | — | $1.06M | |||||||
| Branded Products Nda | — | — | — | — | |||||||
| License & Service | — | — | — | — | |||||||
| Unscheduled Products Licensing Fees | — | — | $1.81M | $594.49K | |||||||
| Scheduled Products Licensing Fees | — | — | $248.79K | $465.51K | |||||||
| Total | $34.16M | $56.63M | $84.04M | $149.93M |
Elite Pharmaceuticals brought in $149.93M from its five product and service lines in fiscal 2026, the year ended March 31, 2026. Elite Pharmaceuticals regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $84.04M. Indirect Sales To Wholesalers was the largest at $82.54M (55.0%), ahead of Direct Sales To Wholesalers at $65.27M (43.5%) and Licensing at $1.06M (0.7%). The other two lines brought in $1.06M combined.
Compared with fiscal 2025, Indirect Sales To Wholesalers grew 142.9% to $82.54M and Direct Sales To Wholesalers grew 36.0% to $65.27M.
Elite Pharmaceuticals began breaking out Indirect Sales To Wholesalers in fiscal 2025, Direct Sales To Wholesalers in fiscal 2025, Unscheduled Products Licensing Fees in fiscal 2025 and Scheduled Products Licensing Fees in fiscal 2025. Elite Pharmaceuticals stopped reporting Manufacturing as a separate line after fiscal 2024, when it brought in $54.12M.
Manufacturing Fees was Elite Pharmaceuticals’s largest segment in fiscal 2021, bringing in $21.00M of $25.21M (83%).
| Segment | FY 2020 | FY 2021 |
|---|---|---|
| Manufacturing Fees | $14.53M | $21.00M |
| Licensing Fees | $2.47M | $4.22M |
| Total | $16.99M | $25.21M |
Elite Pharmaceuticals brought in $25.21M from its two segments in fiscal 2021, the year ended March 31, 2021. That was up 48.4% from $16.99M in fiscal 2020. Manufacturing Fees was the largest at $21.00M (83.3%), ahead of Licensing Fees at $4.22M (16.7%).
Compared with fiscal 2020, Licensing Fees grew 70.8% to $4.22M and Manufacturing Fees grew 44.5% to $21.00M.
Elite Pharmaceuticals (ELTP) reports its revenue by product and service and by segment. In fiscal 2026, Indirect Sales To Wholesalers was its largest product and service line, bringing in $82.54M (55.0% of the total), followed by Direct Sales To Wholesalers at $65.27M (43.5%).
Indirect Sales To Wholesalers was Elite Pharmaceuticals' largest product and service line in fiscal 2026, bringing in $82.54M, or 55.0% of the $149.93M total across its five product and service lines.
Manufacturing Fees was Elite Pharmaceuticals' largest segment in fiscal 2021, bringing in $21.00M, or 83.3% of the $25.21M total across its two segments.
Licensing Fees grew faster than Manufacturing Fees in fiscal 2021, up 70.8% from $2.47M to $4.22M. Manufacturing Fees grew 44.5% to $21.00M.
Every figure comes from Elite Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Elite Pharmaceuticals gives it, and years follow its fiscal calendar.
Elite Pharmaceuticals' revenue by product and service goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.